MARKET

TCRX

TCRX

Tscan Therapeutics, Inc.
NASDAQ
1.000
-0.110
-9.91%
After Hours: 1.020 +0.02 +1.97% 16:18 05/15 EDT
OPEN
1.080
PREV CLOSE
1.110
HIGH
1.100
LOW
1.000
VOLUME
840.89K
TURNOVER
--
52 WEEK HIGH
2.570
52 WEEK LOW
0.8824
MARKET CAP
65.35M
P/E (TTM)
-1.0445
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TCRX last week (0504-0508)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Knight Therapeutics (OtherKHTRF) and TScan Therapeutics (TCRX)
TipRanks · 05/08 18:40
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
TipRanks · 05/07 10:16
TScan Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $1M misses by $1.5M
Seeking Alpha · 05/07 07:19
Analysts Are Bullish on These Healthcare Stocks: Geron (GERN), Regeneron (REGN)
TipRanks · 05/06 20:30
H.C. Wainwright Sticks to Their Buy Rating for TScan Therapeutics (TCRX)
TipRanks · 05/06 16:37
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Protagonist Therapeutics (PTGX) and Disc Medicine (IRON)
TipRanks · 05/06 16:33
TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate
Benzinga · 05/06 11:12
More
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.

Webull offers Tscan Therapeutics Inc stock information, including NASDAQ: TCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCRX stock methods without spending real money on the virtual paper trading platform.